Literature DB >> 10532586

Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction.

C Rizza1, N Leitinger, J Yue, D J Fischer, D A Wang, P T Shih, H Lee, G Tigyi, J A Berliner.   

Abstract

Lysophosphatidic acid (LPA) is produced by a variety of activated cell types and acts as an intercellular mediator of processes associated with inflammation and repair including platelets aggregation, and smooth muscle and fibroblast proliferation. However no previous studies have examined the effects of LPA on endothelial cell leukocyte interactions. We have examined the ability of LPA to activate human aortic endothelial cells (HAEC) to bind monocytes, neutrophils, and HL60 cells (a neutrophil surrogate). Treatment of HAEC for 4 hours with 10 microM LPA caused an increase in the binding of monocytes, neutrophils, and HL60. LPA but not phosphatidic acid dose-dependently increased E-selectin and vascular cell adhesion molecule-1 (VCAM-1) cell surface expression. We performed several studies to characterize the receptor mediating the LPA effect. We demonstrate that at least five potential LPA receptors are expressed by HAEC: Edg-1, -3, -4, and -5 as well as PSP24. Cyclic phosphate-containing phosphatidic acid analogue, an agonist for the type 3 low affinity LPA receptor, was not effective in activating HAEC to bind leukocytes, excluding a role for this receptor. The selective receptor antagonists N-palmitoyl-serine and N-palmitoyl-tyrosine (which inhibits PSP24) completely inhibited LPA-induced VCAM expression; however these antagonists inhibited E-selectin expression by only 30%, suggesting a role for at least one additional LPA receptor mediating E-selectin expression. We propose that Edg-1 might be the second receptor, because this receptor, when expressed in HEK293 cells, similarly to the PSP24 receptor, caused ERK activation to nanomolar concentration of LPA. Exposure of HAEC to sphingosine-1-phosphate, another Edg-1 receptor agonist, increased surface expression of E-selectin and to a much smaller extent VCAM-1. The effects of both LPA and sphingosine-1-phosphate on the induction of both VCAM-1 and E-selectin expression was abolished by pretreatment with pertussis toxin suggesting that both LPA receptors in HAEC couple to a Gi pathway. These findings reveal an important and novel role for LPA and its receptors in inflammatory processes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10532586

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  31 in total

1.  Lysophosphatidic acid effects on atherosclerosis and thrombosis.

Authors:  Mei-Zhen Cui
Journal:  Clin Lipidol       Date:  2011-08

2.  Sphingosine 1-phosphate activates Weibel-Palade body exocytosis.

Authors:  Kenji Matsushita; Craig N Morrell; Charles J Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-23       Impact factor: 11.205

3.  Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells.

Authors:  Zachary Fulkerson; Tao Wu; Manjula Sunkara; Craig Vander Kooi; Andrew J Morris; Susan S Smyth
Journal:  J Biol Chem       Date:  2011-08-10       Impact factor: 5.157

Review 4.  Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance.

Authors:  Mu-En Lin; Deron R Herr; Jerold Chun
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-03-04       Impact factor: 3.072

5.  Identification of non-lipid LPA3 antagonists by virtual screening.

Authors:  James I Fells; Ryoko Tsukahara; Yuko Fujiwara; Jianxiong Liu; Donna H Perygin; Daniel A Osborne; Gabor Tigyi; Abby L Parrill
Journal:  Bioorg Med Chem       Date:  2008-04-18       Impact factor: 3.641

6.  Lysophosphatidic acid causes endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells.

Authors:  Chanygi Chen; Lyssa N Ochoa; Anna Kagan; Hong Chai; Zhengdong Liang; Peter H Lin; Qizhi Yao
Journal:  Atherosclerosis       Date:  2012-02-13       Impact factor: 5.162

7.  Atherosclerotic lesion progression changes lysophosphatidic acid homeostasis to favor its accumulation.

Authors:  Martine Bot; Ilze Bot; Rubén Lopez-Vales; Chris H A van de Lest; Jean Sébastien Saulnier-Blache; J Bernd Helms; Samuel David; Theo J C van Berkel; Erik A L Biessen
Journal:  Am J Pathol       Date:  2010-04-29       Impact factor: 4.307

Review 8.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

9.  Interleukin-1β expression is required for lysophosphatidic Acid-induced lymphangiogenesis in human umbilical vein endothelial cells.

Authors:  Chih-Hsin Lin; Jenher Lu; Hsinyu Lee
Journal:  Int J Inflam       Date:  2010-08-04

Review 10.  Therapeutic potential of autotaxin/lysophospholipase d inhibitors.

Authors:  Lorenzo Federico; Zehra Pamuklar; Susan S Smyth; Andrew J Morris
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.